Hepatotoxicity and antiretroviral therapy with protease inhibitors: A review.
about
Drug Induced Liver Injury: Review with a Focus on Genetic Factors, Tissue Diagnosis, and Treatment OptionsTransgenic mice and metabolomics for study of hepatic xenobiotic metabolism and toxicityGenome-wide association study identified ITPA/DDRGK1 variants reflecting thrombocytopenia in pegylated interferon and ribavirin therapy for chronic hepatitis CRole of ITPA gene polymorphism in ribavirin-induced anemia and thrombocytopenia in Egyptian patients with chronic hepatitis C.Risk of Acute Liver Injury With Antiretroviral Therapy by Viral Hepatitis Status.Brain dysfunction in the era of combination antiretroviral therapy: implications for the treatment of the aging population of HIV-infected individualsHIV protease inhibitors in gut barrier dysfunction and liver injury.HIV-1, HCV and alcohol in the CNS: potential interactions and effects on neuroinflammation.Metabolomic screening and identification of the bioactivation pathways of ritonavirHIV drug resistance early warning indicators in cohorts of individuals starting antiretroviral therapy between 2004 and 2009: World Health Organization global report from 50 countries.'Les liaisons dangereuses': Hepatitis C, Rituximab and B-cell non-Hodgkin's lymphomas.Transient Elastography for the Detection of Liver Damage in Patients with HIVThe effect of ritonavir on human CYP2B6 catalytic activity: heme modification contributes to the mechanism-based inactivation of CYP2B6 and CYP3A4 by ritonavirHIV protease inhibitor lopinavir-induced TNF-alpha and IL-6 expression is coupled to the unfolded protein response and ERK signaling pathways in macrophages.Current concepts of mechanisms in drug-induced hepatotoxicity.Clinical syndromes and consequences of antiretroviral-related hepatotoxicity.Drug-drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors.Correlation between polymorphism in the inosine triphosphatase and the reductions in hemoglobin concentration and ribavirin dose during sofosbuvir and ribavirin therapy.Association of ITPA gene variation and serum ribavirin concentration with a decline in blood cell concentrations during pegylated interferon-alpha plus ribavirin therapy for chronic hepatitis C.Effects of NO-Hybridization on the Immunomodulatory Properties of the HIV Protease Inhibitors Lopinavir and Ritonavir.ITPA genetic variants influence efficacy of PEG-IFN/RBV therapy in older patients infected with HCV genotype 1 and favourable IL28B type.The Opportunities of Metabolomics in Drug Safety Evaluation.Lack of interaction of lopinavir solid drug nanoparticles with cells of the immune system.
P2860
Q26781892-76DDFEB1-D000-41DD-8DA6-9189E6903296Q28087473-2D92D9BC-FD8D-47AA-8B9D-B9575BFD3771Q28943467-A4E59411-E032-49BB-83A3-FF6B3568A8F6Q33430028-E7E7E4BA-5AA5-4947-A1B9-41E89195AC95Q33609481-4AF5A45B-18DB-4567-B266-D4FB2084AA9EQ33614467-433CC416-8D3A-4E35-963F-FA491A59C6FEQ34617496-3459BC1B-95F5-48B4-95D5-D558F496EE76Q35596364-E000D76B-A820-4FD6-AB28-4F311BFD226BQ35626853-2B65FB68-4FCE-4634-AADC-7A3E82DF0021Q35917583-A964E50E-DB9B-48D3-A921-55D458C98B4EQ35948807-A137DB6A-875C-4BDB-9B08-1D17EC094C60Q36073396-1FF67083-84CA-488A-A873-D2BF83A2D995Q37193089-221538C0-522F-488C-AD6B-A0CD42ABB848Q37246875-6303ACC2-EB20-4BEC-B5C4-C5B188DF41AEQ37394799-2E6EBF7F-7369-464A-B92C-E4723EFA6246Q37784777-8B1AB9C8-8D96-4D61-AF7C-D2BC6C6BCABBQ38109095-6D231CBC-9B3C-4B8A-B6EF-139BAEF342D4Q40363387-2233BD9F-1EEA-4A09-BEB3-2042E4CDEAC3Q40707640-B914E6C0-0536-4B7F-B729-CC161D244990Q41026728-EB9144C2-A2F8-4F89-8C89-87A06BE49A85Q42223359-EA0BA2A0-CE31-4026-8364-2BD71DBF7B23Q49363622-7738735F-CC0C-439E-A8DB-20EE3624AB3FQ53555823-BA888364-4032-4A98-9C0B-D871072D2E03
P2860
Hepatotoxicity and antiretroviral therapy with protease inhibitors: A review.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Hepatotoxicity and antiretroviral therapy with protease inhibitors: A review.
@ast
Hepatotoxicity and antiretroviral therapy with protease inhibitors: A review.
@en
type
label
Hepatotoxicity and antiretroviral therapy with protease inhibitors: A review.
@ast
Hepatotoxicity and antiretroviral therapy with protease inhibitors: A review.
@en
prefLabel
Hepatotoxicity and antiretroviral therapy with protease inhibitors: A review.
@ast
Hepatotoxicity and antiretroviral therapy with protease inhibitors: A review.
@en
P50
P1476
Hepatotoxicity and antiretroviral therapy with protease inhibitors: A review
@en
P2093
P304
P356
10.1016/J.DLD.2006.01.020
P577
2006-05-02T00:00:00Z